Perspective Therapeutics, Inc. (CATX) Dividend History

Company News

• Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial Results

  Perspective Therapeutics, a radiopharmaceutical company, announced it will report its Q1 2025 financial results and provide a business update on May 12, 2025. The company is developing treatments for cancers using proprietary technology that utilizes the alpha-emitting isotope 212Pb.

  GlobeNewswire Inc.
• Pharma-Biotech Market Development Analysis Report 2025: Growth Opportunities Shaped by a Convergence of Scientific Innovation, Regulatory Evolution, and Market Pressures

  The pharmaceutical and biotechnology industries are entering a transformative era in 2025, shaped by a convergence of scientific innovation, regulatory evolution, and market pressures. Key growth opportunities include radioligand therapeutics in precision oncology, antibody therapies in immunology and inflammation, IT solutions for price transparency, medical co-pilots for clinical trials, APAC CDMOs scaling up, and neuroprotective therapy through strategic partnerships.

  GlobeNewswire Inc.
• Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 in Combination with Nivolumab in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

  Perspective Therapeutics announced the first patient was dosed in a new cohort of a Phase 1/2a trial evaluating the safety of [212Pb]VMT01, a targeted alpha-particle therapy, in combination with nivolumab for the treatment of metastatic melanoma.

  GlobeNewswire Inc.

  Featured Companies: BMY
• Perspective Therapeutics to Provide Business Highlights and Report Full Year 2024 Financial Results

  Perspective Therapeutics, a radiopharmaceutical development company, announced that it will report its full year 2024 financial results and provide a business update on March 26, 2025. The company is developing advanced treatment applications for cancers using proprietary technology that utilizes the alpha-emitting isotope 212Pb.

  GlobeNewswire Inc.
• Perspective Therapeutics to Participate in Upcoming February Investor Conferences

  Perspective Therapeutics, a radiopharmaceutical company, announced that its senior leadership team will participate in upcoming investor conferences. The company is pioneering advanced treatment applications for cancers using its proprietary technology that utilizes the alpha emitting isotope 212Pb.

  GlobeNewswire Inc.